Kerr Douglas reported DYN

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0001814189-26-000007

Machine-readable

Structured copy

Timestamps

Event (reported)

Oct 20, 2026

Published

Oct 22, 2026

Ingested by INSIDER

Nov 5, 02:10 UTC

Last re-read

Nov 5, 02:10 UTC

Extracted facts

Filer

Kerr Douglas

Role

Head of R&D and CMO

Transaction

Grant or awardAs filed: “A”

Asset

Dyne Therapeutics, Inc.

Ticker

DYN

Shares

8,000

Price per share

$0

Execution date (reported)

Oct 20, 2026

Owned after transaction

170.6K shares

Days from execution to publication

2

What this establishes

Kerr Douglas filed this Form 4 reporting a grant or award of DYN on Oct 20, 2026. It became public on Oct 22, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Head of R&D and CMO

Kerr Douglascik:0001814189

Issuer

Dyne Therapeutics, Inc.cik:0001818794

Revision history · 0

No field has changed since this record was first ingested.